REG - Genflow Biosciences - Notice of Annual General Meeting

Genflow BiosciencesAnnouncement

16/05/2023 10:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230516:nRSP5685Za&default-theme=true

RNS Number : 5685Z  Genflow Biosciences PLC  16 May 2023

 

16 May 2023

Genflow Biosciences Plc

("Genflow" or "the Company")

 

Notice of Annual General Meeting

Genflow (LSE: GENF), a UK-based biotechnology company focused on longevity and
the development of therapies to counteract the effects of aging and diseases
associated with advanced age, is pleased to announce that it will hold its
Annual General Meeting ("AGM") at 09:00am on Thursday 8 June 2023 at the
offices of Westend Corporate LLP, 6 Heddon Street, London, W1B 4BT.

The Notice of the AGM ("Notice") and 2023 Form of Proxy are now available on
the Company's website, www.genflowbio.com (http://www.genflowbio.com) , and
have, where applicable, been posted to shareholders. Further details of the
arrangements for this year's AGM are set out in the Notice.

As announced on 24 April 2023, the Company's Annual Report and Accounts for
the year ended 31 December 2022 is also available on the website and has,
where applicable, also been posted to registered shareholders.

For further information please contact:

 Genflow Biosciences Plc
 Dr Eric Leire              +32 477 495 881

 Chief Executive
 Clear Capital Markets Ltd
 Corporate Broker           +44 203 869 6080

 Andrew Blaylock

 

About Genflow

Genflow is a UK-based biotechnology company established in 2020. The Company
is developing gene therapies designed to target the aging process and to
reduce and delay the incidence of age-related diseases. This will be done
through novel therapeutics targeting aging in humans by using adeno-associated
virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene
variant that is found in centenarians into cells.

 

Its mission is to increase our understanding of the factors that control and
impact lifespan. Genflow researches, develops, and commercialises therapeutic
solutions to lengthen health span, the amount of time we live in good health,
creating biological interventions that enable longer and healthier lives.
Genflow is dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging, Genflow
can contribute to a decrease in healthcare costs and lessen the emotional and
societal burden that comes with an aging population.

 

To learn more visit www.genflowbio.com (http://www.genflowbio.com)

 

-Ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAUNSWROWUVARR